73733-81-0

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[[[(2-aminophenyl)amino]thioxomethyl]amino]-, ethyl ester
• CAS NO: 73733-81-0
• Molecular Formula: C15H22N4O2S
• Molecular Weight: 322.431
• Mol File: 73733-81-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[[[(2-aminophenyl)amino]thioxomethyl]amino]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[[[(2-aminophenyl)amino]thioxomethyl]amino]-, ethyl ester(73733-81-0)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[[[(2-aminophenyl)amino]thioxomethyl]amino]-, ethyl ester(73733-81-0)

Safety Data

• Hazardous Substances Data: 73733-81-0(Hazardous Substances Data)

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 58859-46-4 ethyl 4-aminopiperidine-1-carboxylate 
• 73733-70-7 ethyl 4-isothiocyanato-1-piperidinecarboxylate 

Downstream Products

• 83898-30-0 ethyl 4-((1-benzyl-1H-benzo[d]imidazol-2-yl)amino)piperidine-1-carboxylate 
• 68844-77-9 astemizole 
• 75970-64-8 1-[(4-fluorophenyl)methyl]-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 
• 75970-47-7 (1H-benzimidazol-2-yl)-(4-piperidinyl)amine dihydrobromide 
• 84501-68-8 ethyl 4-[[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]amino]-1-piperidinecarboxylate 
• 75970-99-9 norastemizole 
• 1345012-53-4 (4-(2-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)ethyl)piperazin-1-yl)(1H-indol-2-yl)methanone 
• 1345012-52-3 tert-butyl 4-(2-(4-(1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-ylamino)piperidin-1-yl)ethyl)piperazine-1-carboxylate 
• 73734-07-3 (1H-benzimidazol-2-yl)-(1-ethoxycarbonyl-piperidin-4-yl)amine 
• 98244-76-9 {1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-(1-methyl-1H-benzoimidazol-2-yl)-amine 
• 98244-75-8 1-{2-[4-(1-Methyl-1H-benzoimidazol-2-ylamino)-piperidin-1-yl]-ethyl}-4-phenyl-1,4-dihydro-tetrazol-5-one 
• 79278-73-2 (1-Methyl-1H-benzoimidazol-2-yl)-(1-phenethyl-piperidin-4-yl)-amine 
• 75970-51-3 1-methyl-N-(4-piperidinyl)-1H-benzimidazol-2-amine dihydrobromide 

Relevant articles and documents

Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction

Disruption of EZH2-embryonic ectoderm development (EED) protein-protein interaction (PPI) is a new promising cancer therapeutic strategy. We have previously reported the discovery of astemizole, a small-molecule inhibitor targeting the EZH2-EED PPI. Herein, we report the cocrystal structure of EED in complex with astemizole at 2.15 ?. The structure elucidates the detailed binding mode of astemizole to EED and provides a structure-guided design for the discovery of a novel EZH2-EED interaction inhibitor, DC-PRC2in-01, with an affinityKdof 4.56 μM. DC-PRC2in-01 destabilizes the PRC2 complex, thereby leading to the degradation of PRC2 core proteins and the decrease of global H3K27me3 levels in cancer cells. The proliferation of PRC2-driven lymphomas cells is effectively inhibited, and the cell cycle is arrested in the G0/G1 phase. Together, these data demonstrate that DC-PRC2in-01 could be an effective chemical probe for investigating the PRC2-related physiology and pathology and providing a promising chemical scaffold for further development.

Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH 1R, but low affinity to hH4R

In literature, a synergism between histamine H1 and H 4 receptor is discussed. Furthermore, it was shown, that the combined application of mepyramine, a H1 antagonist and JNJ7777120, a H 4 receptor ligand leads to a synergistic effect in the acute murine asthma model. Thus, the aim of this study was to develop new hybrid ligands, containing one H1 and one H4 pharmacophor, connected by an appropriate spacer, in order to address both, H1R and H 4R. Within this study, we synthesized nine hybrid compounds, which were pharmacologically characterized at hH1R and hH4R. The new compounds revealed (high) affinity to hH1R, but showed only low affinity to hH4R. Additionally, we performed molecular dynamic studies for some selected compounds at hH1R, in order to obtain information about the binding mode of these compounds on molecular level.